ATYR
aTyr Pharma, Inc.
There isn't enough reported data to score ATYR yet.
ATYR Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
ATYR's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
ATYR PE Valuation
ATYR has no meaningful PE right now: it lost money over the past year.
ATYR Forward outlook
There aren't enough analyst estimates for ATYR to show an outlook.
ATYR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$22.23 | +$10.57 |
| Q2 2026 | -$25.20 | +$6.40 |
| Q1 2026 | -$29.60 | +$2.40 |
| Q4 2025 | -$32.00 | +$2.40 |
| Q3 2025 | -$32.80 | +$4.00 |
| Q2 2025 | -$31.60 | +$4.00 |
| Q1 2025 | -$32.00 | +$3.20 |
| Q4 2024 | -$34.40 | +$3.20 |
ATYR is still losing money, but far less than before: $22.23 per share over the past year, against $293.20 at its worst in late 2019.
ATYR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2020 | $2.1M | +1326% |
ATYR's revenue is growing: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2025 | -14076% | N/A |
| Q1 2024 | -7079% | N/A |
| Q3 2023 | -3574% | N/A |
| Q4 2020 | -241% | +3900 points |
| Q3 2020 | -4400% | N/A |
| Q2 2020 | -3343% | N/A |
| Q1 2020 | 23% | N/A |
| Q4 2019 | -4140% | N/A |
ATYR's operating margin was −14076% last quarter, down 9676 points from the same quarter a year ago, near the bottom of its range since 2019.
ATYR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$9.6M | +$11M |
| Q2 2026 | -$9.4M | +$4.5M |
| Q1 2026 | -$12.7M | +$2.8M |
| Q4 2025 | -$12.2M | +$930K |
| Q3 2025 | -$20.5M | -$7.3M |
| Q2 2025 | -$13.9M | +$6.6M |
| Q1 2025 | -$15.4M | +$7M |
| Q4 2024 | -$13.2M | -$2.1M |
ATYR has burned cash in almost every quarter: −$44M over the past year, against −$63M the year before.
ATYR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +4.9K shares |
| 1 year | +1.1% | +27.8K shares |
| 3 years | +78% | +1.1M shares |
| 5 years | +918% | +2.2M shares |
ATYR has 2M diluted shares, up 1.1% from a year ago.
ATYR Net Leverage
ATYR's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ATYR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.3 | Oversold |
| Stochastic | 8.9 | Oversold |
ATYR's weekly RSI is 29 (oversold) and its Stochastic is 9 (oversold).
ATYR PE vs Healthcare Sector
ATYR has no meaningful PE right now: it lost money over the past year.
ATYR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.08 | 23% below |
| 20 week MA | $15.3 | 59% below |
| 50 week MA | $24.0 | 74% below |
| 100 week MA | $82.4 | 92% below |
| 200 week MA | $80.1 | 92% below |
ATYR is in a downtrend: it's below all five of its weekly moving averages, and 92% below its 200-week average.
ATYR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $168.0 | $169.2 | +0.7% |
| 2021 | $169.2 | $314.0 | +86% |
| 2022 | $314.0 | $85.6 | -73% |
| 2023 | $85.6 | $56.4 | -34% |
| 2024 | $56.4 | $149.6 | +165% |
| 2025 | $149.6 | $29.7 | -80% |
| 2026 YTD | $29.7 | $6.21 | -79% |
ATYR's yearly returns have swung widely, from +165% in 2024 to −80% in 2025. It's down 79% so far in 2026.